Clinical Trials Browser

Phase 2 × neratinib × Breast × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04886531 2026-03-12

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2 Recruiting

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT07152782 2025-09-03

THUNDER

Phase 2 Not yet recruiting

Breast Cancer With Brain Metastasis

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2 Completed

11 enrolled 12 charts

Breast Neoplasms

NCT05252988 2025-04-01

DIANER

Phase 2 Active not recruiting

Breast Neoplasms

NCT05388149 2025-01-31

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Phase 2 Recruiting

Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT04460430 2022-10-25

NEREA

Phase 2 Terminated

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2 Completed

563 enrolled 16 charts

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Phase 2 Completed

56 enrolled 29 charts

Breast Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT01008150 2021-10-25

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Phase 2 Completed

141 enrolled 16 charts

Breast Neoplasms

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

Advanced Breast Cancer

NCT00915018 2018-08-22

NEFERTT

Phase 2 Completed

479 enrolled 13 charts

Breast Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Phase 2 Completed

136 enrolled 11 charts

Breast Neoplasms, Neoplasms

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2 Completed

233 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis